Literature DB >> 24971434

How common are myeloproliferative neoplasms? A systematic review and meta-analysis.

Glen J Titmarsh, Andrew S Duncombe, Mary Frances McMullin, Michael O'Rorke, Ruben Mesa, Frank De Vocht, Sarah Horan, Lin Fritschi, Mike Clarke, Lesley A Anderson.   

Abstract

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I(2) 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 50.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs.

Entities:  

Mesh:

Year:  2014        PMID: 24971434     DOI: 10.1002/ajh.23690

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  47 in total

1.  Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.

Authors:  Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang
Journal:  Blood Adv       Date:  2019-11-26

2.  Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

Authors:  Ana Paula Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Biomed Rep       Date:  2017-09-05

Review 3.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

4.  Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.

Authors:  M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson
Journal:  J Intern Med       Date:  2020-01-11       Impact factor: 8.989

Review 5.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

Review 6.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.

Authors:  Michael Desborough; Lise J Estcourt; Anna Chaimani; Carolyn Doree; Sally Hopewell; Marialena Trivella; Andreas V Hadjinicolaou; Paresh Vyas; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2016-01-26

Review 8.  Investigation and management of erythrocytosis.

Authors:  Siraj Mithoowani; Marissa Laureano; Mark A Crowther; Christopher M Hillis
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

9.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.

Authors:  Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2021-07-30       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.